Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment

导出原文传递

翻译打印收藏纠错

作者： de Langen, Adrianus J. ^[1] ; Jebbink, M. ^[2] ; Hashemi, Sayed M. S. ^[3] ; Kuiper, Justine L. ^[4] ; de Bruin-Visser, J. ; Monkhorst, Kim ; Thunnissen, Erik ; Smit, Egbert F.

作者单位： Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands ^[1] Vrije Univ Amsterdam, Med Ctr, Dept Pulm Dis, Amsterdam, Netherlands ^[2] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, Amsterdam, Netherlands ^[3] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Pathol, Amsterdam, Netherlands ^[4]

发布时间 2020-06-03

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

The British journal of cancer

2018年119卷5期

558-564页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment

The British journal of cancer

相似文献

The British journal of cancer

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment

The British journal of cancer

相似文献

The British journal of cancer

相关期刊

检索历史清除